DK1158973T3 - Anvendelse af sulfamatderivater til behandling af impulskontrolafvigelser - Google Patents

Anvendelse af sulfamatderivater til behandling af impulskontrolafvigelser

Info

Publication number
DK1158973T3
DK1158973T3 DK00914630T DK00914630T DK1158973T3 DK 1158973 T3 DK1158973 T3 DK 1158973T3 DK 00914630 T DK00914630 T DK 00914630T DK 00914630 T DK00914630 T DK 00914630T DK 1158973 T3 DK1158973 T3 DK 1158973T3
Authority
DK
Denmark
Prior art keywords
icd
impulse control
sulfamate derivatives
control aberrations
harmful
Prior art date
Application number
DK00914630T
Other languages
English (en)
Inventor
Susan L Mcelroy
Original Assignee
Univ Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22396040&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1158973(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Cincinnati filed Critical Univ Cincinnati
Application granted granted Critical
Publication of DK1158973T3 publication Critical patent/DK1158973T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Prostheses (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
DK00914630T 1999-02-24 2000-02-18 Anvendelse af sulfamatderivater til behandling af impulskontrolafvigelser DK1158973T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12133999P 1999-02-24 1999-02-24
PCT/US2000/004187 WO2000050020A2 (en) 1999-02-24 2000-02-18 Use of sulfamate derivatives for treating impulse control disorders

Publications (1)

Publication Number Publication Date
DK1158973T3 true DK1158973T3 (da) 2005-05-30

Family

ID=22396040

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00914630T DK1158973T3 (da) 1999-02-24 2000-02-18 Anvendelse af sulfamatderivater til behandling af impulskontrolafvigelser

Country Status (21)

Country Link
US (1) US6323236B2 (da)
EP (1) EP1158973B1 (da)
JP (1) JP2002537326A (da)
KR (1) KR100697485B1 (da)
CN (1) CN100548290C (da)
AT (1) ATE294577T1 (da)
AU (1) AU779248B2 (da)
BR (1) BR0008477A (da)
CA (1) CA2364949A1 (da)
CZ (1) CZ20013061A3 (da)
DE (1) DE60019904T2 (da)
DK (1) DK1158973T3 (da)
ES (1) ES2238999T3 (da)
HU (1) HUP0200469A3 (da)
IL (1) IL144884A (da)
MX (1) MXPA01008537A (da)
NO (1) NO20014104L (da)
NZ (1) NZ513643A (da)
PT (1) PT1158973E (da)
WO (1) WO2000050020A2 (da)
ZA (1) ZA200106675B (da)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
DE60039508D1 (de) * 1999-03-19 2008-08-28 Abbott Gmbh & Co Kg Methoden zur behandlung der essstörungen
NZ514813A (en) * 1999-04-08 2004-12-24 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7553818B2 (en) 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
EP1825851B8 (en) 1999-06-14 2015-09-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7659256B2 (en) 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
CA2380208A1 (en) * 1999-07-26 2001-02-01 Ortho-Mcneil Pharmaceutical, Inc. Tricyclic monosaccharide derivatives useful in treating acute ischemia-induced neurodegeneration
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US20030225124A1 (en) * 1999-08-31 2003-12-04 Spiridon Spireas Stable formulations of ACE inhibitors, and methods for preparation thereof
US6759437B2 (en) * 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
WO2002003984A2 (en) 2000-07-07 2002-01-17 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x
US6395783B1 (en) 2000-10-23 2002-05-28 Brookhaven Science Associates, Llc Treatment of PCP addiction and PCP addiction-related behavior
US7034036B2 (en) * 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
NZ537490A (en) 2000-10-30 2006-11-30 Ortho Mcneil Pharm Inc Treatment of diabetes and syndrome X using a sulfamate derivate such as topiramate and metformin
AU2002227052A1 (en) 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
UA78211C2 (en) * 2001-07-09 2007-03-15 Ortho Mcneil Pharm Inc Salts of fructopyranose derivatives as anticonvulsant
US7041650B2 (en) * 2001-07-09 2006-05-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivative salts
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003074474A2 (en) 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
CA2479218A1 (en) * 2002-03-21 2003-10-02 Martin C. Hinz Serotonin and catecholamine system segment optimization technology
US20060110325A1 (en) * 2003-02-21 2006-05-25 Hinz Martin C Serotonin and catecholamine segment optimization technology
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
US20040014681A1 (en) * 2002-05-14 2004-01-22 Ralph Ryback Method for treating dermatoses and tissue damage
CN1320886C (zh) * 2002-05-17 2007-06-13 杜克大学 安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
CA2489984A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
WO2004066981A1 (en) * 2003-01-29 2004-08-12 Sun Pharmaceutical Industries Limited Oral controlled release pharmaceutical composition containing metaxalone as active agent
WO2004075724A2 (en) * 2003-02-21 2004-09-10 Hinz Martin C Serotonin and catecholamine system segment optimization technology
MXPA05011008A (es) * 2003-04-17 2006-03-08 Affectis Pharmaceuticals Ag Medios y metodos para diagnosticar y tratar trastornos afectivos.
DK2316456T3 (da) * 2003-04-29 2017-09-11 Orexigen Therapeutics Inc Sammensætninger til at påvirke vægttab omfattende en opioidantagonist og bupropion
CN102172402A (zh) 2003-05-23 2011-09-07 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050137264A1 (en) * 2003-12-22 2005-06-23 Patel Ashish A. Modafinil compositions
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
EP1734955A2 (en) 2004-01-13 2006-12-27 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
JP2007537151A (ja) * 2004-01-29 2007-12-20 ファイザー・プロダクツ・インク γ−アミノ酪酸モジュレータと５−ＨＴ１Ｂ受容体アンタゴニストとの組合せ
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
EP1758600A4 (en) * 2004-06-04 2008-03-05 Mood Man Sciences Llc METHOD AND COMPOSITIONS FOR TREATING MUTUAL DISORDER
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
BRPI0514278A (pt) * 2004-08-24 2008-06-10 Janssen Pharmaceutica Nv derivados de sulfamida de heteroarila benzo-fundida úteis como agentes anti-convulsivante
AU2006249577A1 (en) 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
EP1896002A4 (en) 2005-06-27 2009-11-25 Biovail Lab Int Srl BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
US9498536B2 (en) * 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) * 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US10716749B2 (en) * 2005-11-03 2020-07-21 Palo Alto Investors Methods and compositions for treating a renal disease condition in a subject
EP3132792B1 (en) 2005-11-22 2019-09-11 Nalpropion Pharmaceuticals, Inc. Composition and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8551986B2 (en) * 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
JP4618804B2 (ja) * 2006-03-24 2011-01-26 キヤノン株式会社 情報処理装置及び情報処理方法とコンピュータプログラム
US20070259859A1 (en) * 2006-05-04 2007-11-08 De Bruin Natasja M W J Muscarinic agonists to treat impulse control disorders
TW200812573A (en) 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20110046120A1 (en) * 2006-10-26 2011-02-24 Mclean Hospital Corporation Treatment of impulse control disorders
KR101654176B1 (ko) 2006-11-09 2016-09-09 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
US20100041689A1 (en) * 2006-12-19 2010-02-18 University Of Virginia Patent Foundation Combined Effects of Topiramate and Ondansetron on Alcohol Consumption
CA2677205A1 (en) * 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
WO2008100727A2 (en) * 2007-02-14 2008-08-21 The Trustees Of Columbia University In The City Of New York High-dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders
CA2617688C (en) * 2007-02-22 2015-08-18 Alpex Pharma S.A. Solid dosage formulations containing weight-loss drugs
CA2697990A1 (en) * 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
WO2009035473A2 (en) * 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
EP2255184B1 (en) 2008-02-28 2013-04-24 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) * 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
BRPI0915890A2 (pt) 2008-06-23 2015-11-03 Janssen Pharmaceutica Nv forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2010036977A2 (en) * 2008-09-25 2010-04-01 New England Medical Center Hospitals, Inc. Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions
KR20120092175A (ko) 2009-12-04 2012-08-20 죤 이. 그랜트 카테콜-0-메틸-트랜스퍼라제 저해제를 사용한 충동 제어 장애의 치료
KR20120101588A (ko) * 2010-01-07 2012-09-13 비버스 인크. 탄산탈수효소 억제제 및 추가적인 활성제의 조합에 의한 폐쇄 수면 무호흡 증후군의 치료
AU2011203867B2 (en) 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
IL278149B2 (en) 2010-07-02 2024-03-01 Univ Virginia Patent Foundation A molecular genetic approach to the treatment and diagnosis of alcohol and drug dependence
EA027743B1 (ru) 2011-09-09 2017-08-31 Юниверсити Оф Вирджиния Пэтент Фаундейшн Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости
ES2802048T3 (es) 2012-06-06 2021-01-15 Nalpropion Pharmaceuticals Llc Composición para uso en un método para el tratamiento de sobrepeso y obesidad en pacientes con alto riesgo cardiovascular
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
EP3443959A1 (en) * 2013-12-12 2019-02-20 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds for use in treating or alleviating pain
US10278948B1 (en) 2015-09-03 2019-05-07 Tian Xia Method for transnasal delivery of anticonvulsant and therapeutic treatments
US10201616B2 (en) 2016-06-07 2019-02-12 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN107595849A (zh) * 2017-10-25 2018-01-19 桂林浩新科技服务有限公司 一种抗焦虑并改善睡眠的药物组合物及其用途
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
EP3955918A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
ATE224189T1 (de) * 1996-06-28 2002-10-15 Ortho Mcneil Pharm Inc Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit
US5753693A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
WO2000023059A2 (en) 1998-10-20 2000-04-27 Ortho-Mcneil Pharmaceutical, Inc. Use of anticonvulsant derivatives for treating alcohol dependency
PT1148874E (pt) * 1999-02-01 2004-04-30 Ortho Mcneil Pharm Inc Uso de derivados anticonvulsivos para o tratamento da bulimia nervosa
AU4050100A (en) 1999-04-08 2000-11-14 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
MXPA01011014A (es) 1999-04-30 2003-06-30 Johnson & Johnson Derivados anticonvulsivos utiles en el tratamiento de dependencia de cocaina.
DE19926758A1 (de) 1999-06-11 2000-12-14 Basf Ag Verfahren zur Verhinderung unerwünschter Polymerisation in einem ethylenisch ungesättigte Verbindungen enthaltenden Stoffgemisch

Also Published As

Publication number Publication date
JP2002537326A (ja) 2002-11-05
CA2364949A1 (en) 2000-08-31
DE60019904T2 (de) 2006-05-04
HUP0200469A2 (hu) 2002-05-29
ES2238999T3 (es) 2005-09-16
CN1360500A (zh) 2002-07-24
US20010023254A1 (en) 2001-09-20
PT1158973E (pt) 2005-07-29
AU3599400A (en) 2000-09-14
EP1158973B1 (en) 2005-05-04
WO2000050020A2 (en) 2000-08-31
NO20014104L (no) 2001-10-16
AU779248B2 (en) 2005-01-13
CZ20013061A3 (cs) 2002-06-12
HUP0200469A3 (en) 2003-03-28
CN100548290C (zh) 2009-10-14
KR100697485B1 (ko) 2007-03-20
IL144884A (en) 2006-12-10
KR20020015306A (ko) 2002-02-27
BR0008477A (pt) 2002-01-22
ATE294577T1 (de) 2005-05-15
US6323236B2 (en) 2001-11-27
EP1158973A2 (en) 2001-12-05
NZ513643A (en) 2005-04-29
DE60019904D1 (de) 2005-06-09
ZA200106675B (en) 2002-05-17
MXPA01008537A (es) 2005-02-17
NO20014104D0 (no) 2001-08-23
WO2000050020A3 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
DK1158973T3 (da) Anvendelse af sulfamatderivater til behandling af impulskontrolafvigelser
YU54896A (sh) (methilsulfonil)fenil-2-(5h)-furanoni kao cox-2 inhibitori
ATE242213T1 (de) Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz
ATE279406T1 (de) Piperidinderivate mit tachykinin-antagonistischer wirkung
DE69327541T2 (de) 4-arylmethyloxymethyl piperidine als tachykinin antagonisten
DK0647219T3 (da) Derivater i vitamin D-serien modificeret i 20-positionen, fremgangsmåde til fremstilling af sådanne derivater, mellemprodukter itl brug ved fremgangsmåde, farmaceutiske præparater indeholdende derivaterne samt deres anvendelse ved fremstilling af lægemidler
NO20045486L (no) Nye forbindelser og deres anvendelse
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
NO20060718L (no) Substituerte tiofoner og deres anvendelse
DK0659427T3 (da) 2-Phenyl-3-azoylbenzothiophener til forøgelse af thrombomodulinekspression
MA28286A1 (fr) Dérivés de 1-N-phenyl-amino-1H-imidazole et compositions pharmaceutiques les contenant
BR0309558A (pt) Derivados de quinazolina e medicamentos
EA200500882A1 (ru) N-арилсульфонил-3-аминоалкоксииндолы
DE60024857D1 (de) Neue verbindungen
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
ES2073258T3 (es) Nuevos derivados de la urea, su preparacion y su aplicacion en terapeutica.
BR0313000A (pt) Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente
KR960003719A (ko) 녹내장 치료제 및 안압 강하제
DE69330283D1 (de) Neue 4-(3-benzofuranyl) piperidinyl und 4-(3-benzothienyl) piperidinyl-derivate und diese enthaltende pharmazeutische zusammenstellungen
PE57194A1 (es) Hidroxiurea de fenoxifenil ciclopentenil
PT973743E (pt) Composicoes farmaceuticas que incorporam compostos olefinicos de amina substituidos com arilo
SE0004462D0 (sv) Novel method and use
ATE160566T1 (de) Amphotere tricyclische verbindungen als antihistaminische und antiallergische mittel
DE60224509D1 (de) Imidazolderivate verwendbar als histamin h3 rezeptorliganden